prog_1

5 ms·

1.
by prog_1 1y ago
enough for what?
2.
by prog_1 1y ago
im glad for you and every single patient that benefits from something i work on. From the public health angle of most eu countries investment into novel cancer treatments makes a lot less sense that improving prevention.
3.
by prog_1 1y ago
not "war on cancer" and not "we" winning. It's pharma finding ways how to profit from rare treatment successes of few rare disease types. Majority, and by majority i mean over 80%, of patients and cancer types are s
4.
by prog_1 2y ago
you surely mean that both are ensemble models. RFs and GBMs differ in how they fit the data
5.
by prog_1 2y ago
ie when you cant beat them, make new metrics and you can absolutely evaluate how smart someone is in a 2min casual conversation. You wont be able to tell how well they are in some niche topic, but %insert something about different flavors o
6.
by prog_1 2y ago
levins work is great, except that afaik it hasnt been reproduced outside of his lab
7.
by prog_1 3y ago
this really depends who you are listening to, eg compare some archetypical bigroom corporate techno performer like Charlotte deWitte vs some crate digger like Om Unit, or since we talk about techno, uhm, Tommy Fourseven
8.
by prog_1 3y ago
continuous bioreactors are a pain to operate due to high risk of contamination, need for precise environment control and validation protocols. They have also been known for decades and are extensively used in process development. Despite al
9.
by prog_1 5y ago
moderation is the key combine and synthesize the best of antifragility, postmodernism, dao te ching, science and what have you this article made step #2 of thesis, antithesis, synthesis.
10.
by prog_1 10y ago
Doesn't anybody have a problem that the nature of their approach is first and foremost prohibition?